Rx-360 Consortium Aims to Curb Pharmaceutical Supply Chain Threats
This article was originally published in The Gold Sheet
Rx-360 Consortium answers the call to develop a global solution to the pharmaceutical supply chain crisis exemplified by last year's heparin adulteration. The consortium, which brings a holistic perspective and a bias for action, will meet June 5 in Washington to chart its course. Its three-year plan calls for adopting and when necessary setting standards, identifying and sharing potential adulteration threats such as the current shortage of acetonitrile, sharing information from audits of suppliers and developing new technologies with the help of research universities. The group envisions a flexible audit-sharing system that could include second- and third-party audits that might be built on an IT platform originally developed to share audits of working conditions.
You may also be interested in...
Just as they did during the heparin crisis a decade ago, pharmaceutical companies must coordinate on coronavirus, Rx-360 CEO says.
FDA’s risk communications cannot outpace counterfeiters, advisory committee member warns, citing the need for more rigorous supply chain controls; meanwhile, agency’s counterfeit drug alerts aimed at physicians draw industry praise.
Rx-360 International Pharmaceutical Supply Chain Consortium plans to share information about the quality and safety of ingredients purchased from common suppliers.